Insider Selling: Natera (NASDAQ:NTRA) CFO Sells $5,621,553.52 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 23,948 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $5,621,553.52. Following the completion of the sale, the chief financial officer owned 99,776 shares in the company, valued at approximately $23,421,418.24. This trade represents a 19.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50.
• On Wednesday, October 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $190.64, for a total transaction of $355,924.88.
• On Tuesday, October 28th, Michael Burkes Brophy sold 2,415 shares of Natera stock. The shares were sold at an average price of $191.16, for a total transaction of $461,651.40.
• On Monday, October 27th, Michael Burkes Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $150,201.92.
• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $196.77, for a total value of $148,561.35.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $241.58 on Friday. The company has a market capitalization of $33.42 billion, a PE ratio of -105.49 and a beta of 1.62. The stock has a fifty day moving average of $234.18 and a 200-day moving average of $191.40. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36.

Natera (NASDAQ:NTRA) last announced its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period last year, the firm earned ($0.26) earnings per share. As a group, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Natera by 44.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after buying an additional 3,263,822 shares during the period. Norges Bank bought a new position in shares of Natera during the 2nd quarter worth approximately $277,749,000. Franklin Resources Inc. grew its holdings in shares of Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after purchasing an additional 727,366 shares during the last quarter. AQR Capital Management LLC grew its stake in Natera by 39.0% during the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after buying an additional 673,315 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Natera by 215.7% during the 3rd quarter. Millennium Management LLC now owns 527,942 shares of the medical research company’s stock valued at $84,983,000 after purchasing an additional 360,733 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent analyst reports. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. UBS Group lifted their price objective on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Thursday. Evercore ISI raised their target price on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Finally, TD Cowen reissued a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $245.50.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.